Epoetin zeta

Drug Profile

Epoetin zeta

Alternative Names: 1-165-Erythropoietin (human clone B03XA01), glycoform zeta; Darbepoetin alfa biosimilar - Bioceuticals; Darbepoetin alfa biosimilar - Hospira; Darbepoetin alfa biosimilar - Stada; Darbepoetin biosimilar - Bioceuticals; Darbepoetin biosimilar - Hospira; Darbepoetin biosimilar - Stada; Epo-zeta; Epoetin alfa biosimilar - Bioceuticals; Epoetin alfa biosimilar - Hospira; Epoetin alfa biosimilar - Stada; Epoetin biosimilar - Bioceuticals; Epoetin biosimilar - Hospira; Epoetin biosimilar - Stada; Epoetin Hospira; Erythropoietin alfa - Bioceuticals; Erythropoietin alfa - Stada; Erythropoietin alfa biosimilar - Hospira; Retacrit; SB 309; Silapo

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIOCEUTICALS Arzneimittel
  • Developer Hospira; STADA Arzneimittel
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 15 May 2018 Registered for Anaemia in Puerto Rico (IV)
  • 15 May 2018 Registered for Anaemia in USA (IV)
  • 15 May 2018 Registered for Anaemia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top